Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Wuxi Biologics (Cayman) ( (HK:2269) ).
WuXi Biologics (Cayman) Inc. has announced the composition of its board of directors and their roles within the company. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to various committees such as Audit, Remuneration, Nomination, Strategy, and Environmental, Social and Governance. This announcement reflects the company’s commitment to strong governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$30.94 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. operates in the biopharmaceutical industry, focusing on providing end-to-end solutions for biologics discovery, development, and manufacturing.
Average Trading Volume: 57,849,643
Technical Sentiment Signal: Buy
Current Market Cap: HK$102.5B
For detailed information about 2269 stock, go to TipRanks’ Stock Analysis page.